Literature DB >> 15304099

Longitudinal assessment of the nevus phenotype in a melanoma kindred.

Scott R Florell1, Laurence J Meyer, Kenneth M Boucher, Patricia A Porter-Gill, Marybeth Hart, Jennica Erickson, Lisa A Cannon-Albright, Lynn K Pershing, Ronald M Harris, Wolfram E Samlowski, John J Zone, Sancy A Leachman.   

Abstract

Phenotypic characteristics of members of a melanoma prone kindred with a V126D CDKN2A gene mutation were monitored over approximately 15 y. Thirty-eight previously studied subjects were recruited. Participants underwent a complete skin examination by the same dermatologist who examined them initially. The size and location of all nevi were recorded on a body map diagram. Total nevus number (TNN) and total nevus density (TND) were determined. CDKN2A sequencing verified 13 mutation carriers and 16 non-carriers. Nine participants were spouse controls without a history of melanoma and did not carry a CDKN2A mutation. Mutation carriers demonstrated a greater mean TNN and TND at initial and follow-up examinations compared with non-carriers and continued to develop nevi rather than show nevus regression seen in non-carriers and spouse controls. Non-carriers showed an intermediate nevus phenotype between mutation carriers and spouse controls. Four of the 13 mutation carriers and one non-carrier have developed invasive melanoma. Over a 15-y interval, TNN and TND were increased in mutation carriers compared with non-carriers and spouse controls. Continued accumulation of nevi in mutation carriers supports a nevogenic role for this CDKN2A mutation. An intermediate nevus phenotype in non-carrier family members suggests the presence of additional modifier genes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15304099     DOI: 10.1111/j.0022-202X.2004.23312.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  7 in total

1.  Germline Variation at CDKN2A and Associations with Nevus Phenotypes among Members of Melanoma Families.

Authors:  Nicholas J Taylor; Nandita Mitra; Alisa M Goldstein; Margaret A Tucker; Marie-Françoise Avril; Esther Azizi; Wilma Bergman; D Timothy Bishop; Brigitte Bressac-de Paillerets; William Bruno; Donato Calista; Lisa A Cannon-Albright; Francisco Cuellar; Anne E Cust; Florence Demenais; David E Elder; Anne-Marie Gerdes; Paola Ghiorzo; Thais C Grazziotin; Johan Hansson; Mark Harland; Nicholas K Hayward; Marko Hocevar; Veronica Höiom; Christian Ingvar; Maria Teresa Landi; Gilles Landman; Alejandra Larre-Borges; Sancy A Leachman; Graham J Mann; Eduardo Nagore; Håkan Olsson; Jane M Palmer; Barbara Perić; Dace Pjanova; Antonia Pritchard; Susana Puig; Nienke van der Stoep; Karin A W Wadt; Linda Whitaker; Xiaohong R Yang; Julia A Newton Bishop; Nelleke A Gruis; Peter A Kanetsky
Journal:  J Invest Dermatol       Date:  2017-08-19       Impact factor: 8.551

Review 2.  Melanoma genetics and the development of rational therapeutics.

Authors:  Yakov Chudnovsky; Paul A Khavari; Amy E Adams
Journal:  J Clin Invest       Date:  2005-04       Impact factor: 14.808

Review 3.  Melanocytic nevi and melanoma: unraveling a complex relationship.

Authors:  W E Damsky; M Bosenberg
Journal:  Oncogene       Date:  2017-06-12       Impact factor: 9.867

Review 4.  The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia.

Authors:  Boris C Bastian
Journal:  Annu Rev Pathol       Date:  2014       Impact factor: 23.472

5.  Nevus senescence.

Authors:  Andrew L Ross; Margaret I Sanchez; James M Grichnik
Journal:  ISRN Dermatol       Date:  2011-06-22

6.  Cutaneous melanoma primary site is linked to nevus density.

Authors:  Alejandro Martin-Gorgojo; Marta Llinares; Amaya Virós; Celia Requena; Zaida Garcia-Casado; Víctor Traves; Rajiv Kumar; Eduardo Nagore
Journal:  Oncotarget       Date:  2017-10-24

Review 7.  Current Molecular Markers of Melanoma and Treatment Targets.

Authors:  Kevin Yang; Allen S W Oak; Radomir M Slominski; Anna A Brożyna; Andrzej T Slominski
Journal:  Int J Mol Sci       Date:  2020-05-16       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.